Who are docetaxel and carboplatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): docetaxel - cisplatin - 5-fluorouracil, paclitaxel plus carboplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-and-carboplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

docetaxel and carboplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

docetaxel and carboplatin (docetaxel and carboplatin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane and platinum-based chemotherapy. Area: Oncology.

phase 3 Taxane and platinum-based chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

docetaxel and carboplatin (docetaxel and carboplatin) — Sanofi. Docetaxel is a microtubule inhibitor that disrupts cell division, while carboplatin is a platinum-based alkylating agent that cross-links DNA, both leading to cell death.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
docetaxel and carboplatin TARGET	docetaxel and carboplatin	Sanofi	phase 3	Taxane and platinum-based chemotherapy
docetaxel - cisplatin - 5-fluorouracil	docetaxel - cisplatin - 5-fluorouracil	Gruppo Oncologico del Nord-Ovest	phase 3	Taxane and platinum-based chemotherapy	Microtubules and DNA
paclitaxel plus carboplatin	paclitaxel plus carboplatin	Immatics US, Inc.	phase 3	Taxane and platinum-based chemotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane and platinum-based chemotherapy class)

Gruppo Oncologico del Nord-Ovest · 1 drug in this class
Immatics US, Inc. · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). docetaxel and carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-and-carboplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab